All Blogs

Apr 01, 2025

Sanofi’s Qfitlia Becomes First US-Approved Therapy for Hemophilia A or B The FDA has approved Qfitlia (fitusiran), the first antithrombin-lowering therapy for routine prophylaxis to prevent or reduce bleeding episodes in hemophilia A or hemophilia B patients (ages 12+) with or without inhibitors. Approval is bas...

Mar 27, 2025

Alcon Announced CE Mark Approval and Launch of Clareon Vivity IOL in Europe, Expanding Visual Options  On March 25, 2025, Alcon, the global leader in eye care committed to enhancing vision, announced that Vivity®, the most widely implanted extended depth of focus (EDOF) intraocular lens (IOL), became availa...

Mar 26, 2025

Obesity is a chronic disease reaching alarming levels worldwide, leading to diabetes, cardiovascular disease, and metabolic disorders. It results from a mix of genetic, environmental, and lifestyle factors. Understanding what are the reasons for obesity—poor diet, inactivity, and hormonal imbalances—is crucial. Key...

Mar 25, 2025

Clover’s RSV Vaccine Candidate SCB-1019 Gains U.S. IND Clearance for Revaccination Study Clover Biopharmaceuticals, Ltd. has received FDA clearance for its Investigational New Drug (IND) application and has initiated a Phase I revaccination clinical trial for SCB-1019, its non-adjuvanted bivalent RSV prefusion-s...

Mar 31, 2025

MPS I treatment typically involves Hematopoietic Stem Cell Transplantation (HSCT), Enzyme Replacement Therapy (ERT), or a combination of both, along with supportive care such as pain management, anti-inflammatory medications, oxygen therapy, and surgery. While these MPS I treatments help manage symptoms and improve...

Mar 24, 2025

Mucopolysaccharidosis Type I (MPS I) is a rare genetic disorder caused by a deficiency of the enzyme α-L-iduronidase, leading to the buildup of complex sugars in the body. This progressive condition can impact multiple organs, causing skeletal abnormalities, vision, and hearing loss, and even cognitive decline.&nbs...

Mar 20, 2025

Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in the Netherlands  On March 18, 2025, Telix announced that its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), received marketing authorization from the Medicines Evaluation Board (MEB) in t...

Mar 21, 2025

Neurotech Pharmaceuticals has achieved a significant milestone with the recent FDA approval of its encapsulated cell therapy implant, revakinagene taroretcel, branded as ENCELTO. Approved on March 6, 2025, ENCELTO is the first treatment authorized by the FDA for macular telangiectasia (MacTel) type 2, a rare neurod...

Mar 28, 2025

Non-small cell lung cancer (NSCLC) remains one of the toughest cancers to treat, but bispecific antibodies (BsAbs) are changing the game. Unlike traditional therapies, BsAbs are engineered to target two different antigens simultaneously, enhancing precision and boosting immune response. This dual-targeting approach...

Mar 19, 2025

Mucopolysaccharidosis (MPS) is a group of rare genetic disorders affecting roughly 1 in 25,000 births, yet its impact is profound. Caused by enzyme deficiencies, MPS leads to the buildup of complex sugars in cells, resulting in progressive damage to the heart, bones, brain, and other organs. Symptoms can vary widel...